Search research articles
Contact Us
Filters
Showing results (41-50 of 161) with videos related to
Page
of 17
Sort By:
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
Geoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
Mark R Middleton, Emma Dean, Thomas R J Evans, et al.
Frontiers in Immunology
|
February 13, 2023
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Kristian C Williams, Abigail Gault, Amy E Anderson, et al.
Clinical Lung Cancer
|
February 22, 2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker
Rodryg Ramlau, Michael Thomas, Silvia Novello, et al.
British Journal of Cancer
|
March 24, 2020
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
British Journal of Cancer
|
February 21, 2020
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
BMJ Open
|
March 5, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
Tobias Menne, Daniel Slade, Joshua Savage, et al.
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Ruth Plummer, Ayman Madi, Melinda Jeffels, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib
Diane D Wang, Chunze Li, Wan Sun, et al.
Journal of Hepatology
|
May 2, 2016
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?
Laura F Ogle, James G Orr, Catherine E Willoughby, et al.
Page
of 17
Search research articles
Search
Showing results (41-50 of 161) with videos related to
Sort By:
Page
of 17
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib in combination with cisplatin in patients with advanced solid tumours
Geoffrey I Shapiro, Robert Wesolowski, Craig Devoe, et al.
British Journal of Cancer
|
May 27, 2021
Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine ± cisplatin in patients with advanced solid tumours
Mark R Middleton, Emma Dean, Thomas R J Evans, et al.
Frontiers in Immunology
|
February 13, 2023
Immune-related adverse events in checkpoint blockade: Observations from human tissue and therapeutic considerations
Kristian C Williams, Abigail Gault, Amy E Anderson, et al.
Clinical Lung Cancer
|
February 22, 2015
Phase I Study of Lapatinib and Pemetrexed in the Second-Line Treatment of Advanced or Metastatic Non-Small-Cell Lung Cancer With Assessment of Circulating Cell Free Thymidylate Synthase RNA as a Potential Biomarker
Rodryg Ramlau, Michael Thomas, Silvia Novello, et al.
British Journal of Cancer
|
March 24, 2020
Correction: A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
British Journal of Cancer
|
February 21, 2020
A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965
Rosie McNeillis, Alastair Greystoke, Jon Walton, et al.
BMJ Open
|
March 5, 2022
Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial
Tobias Menne, Daniel Slade, Joshua Savage, et al.
Cancer Chemotherapy and Pharmacology
|
October 16, 2012
A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
Ruth Plummer, Ayman Madi, Melinda Jeffels, et al.
Clinical Pharmacology in Drug Development
|
April 30, 2016
PARP activity in peripheral blood lymphocytes as a predictive biomarker for PARP inhibition in tumor tissues - A population pharmacokinetic/pharmacodynamic analysis of rucaparib
Diane D Wang, Chunze Li, Wan Sun, et al.
Journal of Hepatology
|
May 2, 2016
Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?
Laura F Ogle, James G Orr, Catherine E Willoughby, et al.
Page
of 17